ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 122

General Practitioners’ Perceptions of Methotrexate and Anti-TNF Therapies: A Qualitative Study

Martin Soubrier1, Sylvain Mathieu2 and Elise Berthet3, 1Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, 2Rheumatology Department, CHU clermont-Ferrand, Clermont-Ferrand, France, 3Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: anti-TNF therapy, methotrexate (MTX) and qualitative

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Health Services Research Poster I: Diagnosis, Management and Treatment Strategies

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Remission of disease is the primary goal in chronic inflammatory arthritis, especially in rheumatoid arthritis. Traditional disease-modifying drugs like methotrexate and anti-tumor necrosis factor (anti TNF) therapy are increasingly prescribed. General practitioners (GP) have to be faced with these treatments.  The aim of the study is to explore GPs’ perceptions of using these treatments in regular day-to-day practice.

Methods:

Semi structured interviews conducted with 14 GPs following patients under methotrexate and anti-TNF therapy, were analysed independently by researchers using inductive thematic analysis.

Results:

Four themes were identified: role of the GP in care delivery to patients under these treatments; their experiences and difficulties with these treatments; their perception of therapy education programmes; improving care delivery practices. The GP’s role revolves around repeat prescription of methotrexate and managing for comorbidities, such as vaccination. In regular day-to-day practice, GPs note good tolerance and efficacy with these treatments. However, the increased risk of infection remains a top-of-mind concern and represents a hindrance to the use of these treatments. The most predominant difficulties are drug interactions and how to handle stopping anti-TNF therapy during bacterial infection, especially for GPs in rural area where there is limited access to specialist care. These GPs also report limited access to therapy education programmes. All the GPs voiced the need for a support tool to help them manage these therapies in routine practice.

Conclusion:

Methotrexate and anti-TNF therapies bring specific management issues that warrant tight cooperation between GPs and specialists. This study finds that it seem essential to facilitate dedicated training for GPs and to deploy a support tool.


Disclosure: M. Soubrier, None; S. Mathieu, None; E. Berthet, None.

To cite this abstract in AMA style:

Soubrier M, Mathieu S, Berthet E. General Practitioners’ Perceptions of Methotrexate and Anti-TNF Therapies: A Qualitative Study [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/general-practitioners-perceptions-of-methotrexate-and-anti-tnf-therapies-a-qualitative-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/general-practitioners-perceptions-of-methotrexate-and-anti-tnf-therapies-a-qualitative-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology